Core Insights - Neo Ivy Capital Management disclosed a new position in Dolby Laboratories, acquiring 117,964 shares valued at approximately $7.58 million on February 13, 2026 [1][2] Company Overview - Dolby Laboratories is a leading provider of audio and imaging innovations, utilizing proprietary technologies to enhance entertainment experiences across various platforms [6] - The company operates a robust licensing model combined with hardware solutions, which supports global reach and recurring revenue streams [6] - As of February 12, 2026, Dolby's stock price was $66.57, with a market capitalization of $6.37 billion and a revenue of $1.34 billion for the trailing twelve months (TTM) [4] Financial Performance - In the first quarter of fiscal 2026, Dolby reported revenue of $347 million, a decrease from $357 million year-over-year, with $319.8 million derived from high-margin licensing streams [11] - The gross profit for the quarter was $303.5 million, and the company generated $53.3 million in GAAP net income [11] - Dolby repurchased approximately 1 million shares for about $70 million, maintaining a buyback authorization balance of $207 million [11] Market Position - Dolby's licensing franchises are characterized by high gross margins of roughly 90%, and the company holds over $640 million in cash and equivalents, indicating a strong balance sheet [12] - The company serves a diverse clientele, including film studios, content creators, post-production facilities, cinema operators, broadcasters, and device manufacturers globally [9] - Despite a decline of 18.2% in share price over the past year, Dolby's fundamentals suggest a more stable outlook, contrasting with its underperformance relative to the S&P 500 by 31.08 percentage points [8][11]